BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Italfarmaco S.p.A. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Italfarmaco S.p.A.'s drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT01761968-3348@assetmemo.bio
DTSTAMP:20261121T005951Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Givinostat: Phase 2 readout est. (NCT01761968)
DESCRIPTION:Givinostat\, phase 2.\nStudy: Long-term Study Evaluating the Ef
 fect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/givinostat#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT01761968
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933057-3348@assetmemo.bio
DTSTAMP:20261121T005951Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Givinostat: Phase 3 readout est. (NCT05933057)
DESCRIPTION:Givinostat\, phase 3\, Duchenne Muscular Dystrophy.\nStudy: Eff
 icacy\, Safety and Tolerability of Givinostat in Non-ambulant Patients Wit
 h Duchenne Muscular Dystrophy\nEstimated primary completion: February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/givinostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05933057
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769633-3348@assetmemo.bio
DTSTAMP:20261121T005951Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Givinostat: Phase 2 readout est. (NCT06769633)
DESCRIPTION:Givinostat\, phase 2\, Duchenne Muscular Dystrophy.\nStudy: Pha
 rmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 
 2 Years to Less Then 6 Years Old\nEstimated primary completion: December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/givinostat#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06769633
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03373968-3348@assetmemo.bio
DTSTAMP:20261121T005951Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Givinostat: Phase 2/3 readout est. (NCT03373968)
DESCRIPTION:Givinostat\, phase 2/3\, Duchenne Muscular Dystrophy.\nStudy: G
 ivinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerabili
 ty Study\nEstimated primary completion: December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/givinostat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03373968
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
